Blog
RSS FeedPosted by Michael Wonder on 28 Aug 2017
NICE terminates appraisal of another cancer medicine
23 August 2017 - NICE has terminated its appraisal of idelalisib with ofatumumab acetate for the treatment of patients with ...
Posted by Michael Wonder on 27 Aug 2017
Breast cancer drug Perjeta at risk in price wrangle
27 August 2017 - Thousands of women with advanced breast cancer could be denied a drug therapy that can extend ...
Posted by Michael Wonder on 27 Aug 2017
NICE reverses stance on Takeda’s Adcetris
25 August 2017 - NICE reverses stance on Takeda’s Adcetris. ...
Posted by Michael Wonder on 23 Aug 2017
NICE rejects thyroid cancer drugs
23 August 2017 - It is looking likely that patients in England will loose NHS access to Ipsen’s Cometriq and ...
Posted by Michael Wonder on 21 Aug 2017
Pfizer objects to NICE methods in leukaemia drug rejection
21 August 2017 - NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give ...
Posted by Michael Wonder on 20 Aug 2017
NICE no takes gloss off Besponsa’s FDA nod
18 August 2017 - Hours after Pfizer announced the news of regulatory approval for its drug Besponsa (inotuzumab ozogamicin) in ...
Posted by Michael Wonder on 14 Aug 2017
NICE turns down kidney cancer drugs
14 August 2017 - It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will ...
Posted by Michael Wonder on 10 Aug 2017
Patients getting faster access to cancer drugs as NICE approves three quarters of the Cancer Drugs Fund
10 August 2017 - Liver cancer drug, sorafenib has been approved for routine NHS use, marking three quarters of the way ...
Posted by Michael Wonder on 09 Aug 2017
NICE supports the use of another treatment option for patients with renal cell carcinoma on the NHS
9 August 2017 - NICE has completed its appraisal of cabozantinib maleate for patients with previously treated advanced renal cell ...
Posted by Michael Wonder on 09 Aug 2017
NICE recommends Erbitux
8 August 2017 - NICE recommends Erbitux in combination with platinum-based chemotherapy for the treatment of recurrent and/or metastatic head and ...
Posted by Michael Wonder on 04 Aug 2017
NICE leans towards a ‘no’ for Keytruda in urothelial cancer
4 August 2017 - Cost regulators for NHS therapies in England and Wales have turned down MSD’s immunotherapy Keytruda as ...
Posted by Michael Wonder on 04 Aug 2017
Pancreatic cancer patients to have routine access to life extending drug after new deal, says NICE
4 August 2017 - NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and ...
Posted by Michael Wonder on 03 Aug 2017
UK finds Roche bladder cancer drug too costly for routine use
3 August 2017 - Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to ...
Posted by Michael Wonder on 02 Aug 2017
Roche invited to submit a CDF proposal for urothelial cancer drug
2 August 2017 - NICE has asked Roche to submit a Cancer Drugs Fund proposal for an immunotherapy treatment called ...
Posted by Michael Wonder on 26 Jul 2017
Roche hails 4 year NICE access deal for Gazyvaro
26 July 2017 - NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the ...